louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02147275: Monitoring Hypertensive Patients's Cerebral Oxygen Saturation
Official title: Monitoring Cerebral Oxygen Saturation in Hypertensive Patients Undergoing Major Abdominal Surgery
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Surgical Complications From General Anesthesia
Hypertension
Cerebral Ischemia
Cerebral Anoxia
Keywords: hypertension
cerebral oxygen saturation
near-infrared spectroscopy
cognitive function
Lead sponsor: Huazhong University of Science and Technology
Sponsor class: OTHER
First posted: 2014-05-26
Enrollment: 41
Sex: ALL
Minimum age (years): 30
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: patients scheduled for major abdominal surgery such as gastrectomy, colon resection ,liver resection and duodenocephalo-pancreasectomy

Brief summary: The purpose of this study is to determine whether there is a significant decrease in cerebral oxygen saturation in hypertensive patients undergoing major abdominal surgery and their correlation with standard monitoring parameters.


Eligibility criteria: Inclusion Criteria:

* patients have hypertension more than 3 year,whether well-controlled or uncontrolled,
* scheduled for major abdominal surgery for at least 2 h
* under general anesthesia
* American Society of Anesthesiologists（ASA）physical status : II \~ III
* Age \> 30

Exclusion Criteria:

* pre-existing cerebral pathology for example episodes of cerebral ischemia or stroke;
* ASA physical status \>IV
* hepatic failure
* renal failure
* preoperative Mini-Mental State Examination (MMSE) score less than 24
* a history of cardiovascular surgery or craniotomy
* cardiac failure
* respiratory failure

Primary outcomes:
measure: decreases in cerebral oxygen saturation (rSO2) during the surgery
timeFrame: every 5 minutes throughout the surgery
Secondary outcomes:
measure: Change from baseline in Mini-Mental State Exam (MMSE) perioperative period
timeFrame: Baseline, 4 day after surgery
Other outcomes:
Locations:
city: Wuhan
country: China
facility: Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology
state: Hubei
Study officials:
affiliation: Vice Director
name: Peng Wang, MD PHD
role: STUDY_DIRECTOR
References:
citation: Li H, Fu Q, Wu Z, Sun J, Manyande A, Yang H, Wang P. Cerebral oxygen desaturation occurs frequently in patients with hypertension undergoing major abdominal surgery. J Clin Monit Comput. 2018 Apr;32(2):285-293. doi: 10.1007/s10877-017-0024-0. Epub 2017 May 9.
Clinical trial NCT00471575: Fatty Liver in Pregnancy
Official title: Prospective Observational Study
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Fatty Liver
Keywords: fatty liver
pregnancy
ultra sound
Pregnant women at the end of pregnancy or immediately after birth.
controls-women with normal liver
correlation between ultrasonography and nutritional, obsthetric and laboratory data.
Lead sponsor: Assaf-Harofeh Medical Center
Sponsor class: OTHER_GOV
First posted: 2007-05-10
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: DEFINED_POPULATION
Time perspective: OTHER

Brief summary: Non alcoholic fatty liver disease (NAFLD) is one of the main causes of development of chronic liver disease and cirrhosis. There are no published studies which have investigated the incidence of NAFLD in pregnant women or the correlation between the metabolic changes in pregnancy and this phenomenon.

We aimed in our study to explore the incidence of NAFLD in pregnancy by ultrasonography (US) during the end of the pregnancy or immediately after birth (after 36 weeks) and to look for a correlation between fatty liver and demographic, clinical, nutritional and laboratory data during pregnancy.

Detailed description: Fatty liver in pregnancy-protocol:

Non alcoholic fatty liver disease (NAFLD) is one of the main causes of development of chronic liver disease and cirrhosis. The incidence of NAFLD among the general population is about 17-30%. There are no published studies which have investigated the incidence of NAFLD in pregnant women or the correlation between the metabolic changes in pregnancy and this phenomenon.

We aimed in our study to explore the incidence of NAFLD in pregnancy by ultrasonography (US) during the end of the pregnancy or immediately after birth (after 36 weeks) and to look for a correlation between fatty liver and demographic, clinical, nutritional and laboratory data during pregnancy.

Methods: US examination will be performed by an experienced technician. The liver will be scanned by B mode US using a 2-5 MHZ transducer. In those with fatty liver as seen by US, a repeat examination will be performed after 6 weeks and 24 weeks. For women with the diagnosis of fatty liver, serum lipid profile, glucose, liver function tests and insulin will be done. Homa score as well as BMI will be calculated for each woman with fatty liver. All participants will sign an informed consent which has been approved by the hospital ethical committee.

Eligibility criteria: Inclusion Criteria:

* Pregnant women during the end of the pregnancy or immediately after birth (after 36 weeks)

Exclusion Criteria:

* Pregnant women before 36 weeks of pregnancy.
* Known diabetes or treatment by drugs known to cause fatty liver.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Zerifin
country: Israel
facility: Assaf Harofeh Medical Center
Study officials:
affiliation: Ethic committee of Assaf Harofeh Medical Center
name: efrat Broide, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT07007975: The Effect of Web-based Education on Gynecological Cancer Awareness and Healthy Life Behaviors
Official title: The Effect of Web-based Gynecological Cancer Awareness on Married Women's Gynecological Cancer Awareness and Healthy Lifestyle Behaviors
Study type: INTERVENTIONAL
Overall status: ENROLLING_BY_INVITATION
Phase: NA
Conditions: Healthy Women
Lead sponsor: Inonu University
Sponsor class: OTHER
First posted: 2025-06-06
Enrollment: 120
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: There are cross-sectional or quasi-experimental studies in the literature on gynecological cancer awareness, but there are no fully experimental studies. The study we will conduct will use a control group and will be a fully experimental study. Thus, it is thought to contribute more to the field. The purpose of the study is to determine the effect of gynecological cancer education given to married women on their gynecological cancer awareness and healthy living behaviors.

Detailed description: The aim of the study was to determine the effect of web-based gynecological cancer education on gynecological cancer awareness and healthy life behaviors of married women. For this purpose, participants were divided into two groups and web-based education was given to the experimental group.

Eligibility criteria: Inclusion Criteria:

* Being between the ages of 20-65
* Being open to communication
* Being literate
* Being able to use the internet
* Having a smart phone or computer

Exclusion Criteria:

* Being pregnant
* Being breastfeeding
* Not being able to use a website
* Not having watched all the videos on the website
* Having a history of gynecological cancer in oneself or in one's family

Primary outcomes:
measure: Gynecological cancer awareness scale
timeFrame: 4 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Malatya
country: Turkey
facility: Family Health Center
Study officials:
affiliation: Inonu University
name: Yurdagül Y Yağmur
role: STUDY_DIRECTOR
References:
Clinical trial NCT00969475: The Effects of Fractional Carbon Dioxide (CO2) Laser Treatment Prior to Wound Closure
Official title: The Effects of Fractional CO2 Resurfacing Prior to Complex Wound Closure
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Scars
Keywords: scar revision
intraoperative
fractional carbon dioxide laser
Lead sponsor: Moy-Fincher Medical Group
Sponsor class: OTHER
First posted: 2009-09-01
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine if fractional carbon dioxide laser treatment of a fresh wound at the time of surgery, decreases scar formation. Scar revision is commonly done at 6-10 weeks following surgery. Therefore, it may be more beneficial, for both the patient and physician, to perform scar revision at the time of surgery.


Eligibility criteria: Inclusion Criteria:

* Undergoing skin cancer surgery
* Will have a straight-line incision
* Fluent in English
* Must reside in the Los Angeles vicinity for the duration of the study

Exclusion Criteria:

* Non-English speakers
* Pregnant or cognitively impaired subjects

Primary outcomes:
measure: Evidence of scar improvement as assessed by blinded-observer and patient ratings.
timeFrame: At two and six weeks following the procedure
Secondary outcomes:
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: Moy-Fincher Medical Group
state: California
Study officials:
affiliation: Moy-Fincher Medical Group
name: David Ozog, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00331175: Safety, Toleration and Pharmacokinetics of Single Intravenous Doses of Peptide YY in Overweight Adults
Official title: A Phase 1, Randomized, Placebo- And Positive Controlled Study To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Single Escalating Doses Of Intravenous Peptide YY3-36 In Otherwise Healthy Overweight Adult Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Obesity
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
First posted: 2006-05-29
Enrollment: 31
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this trial is to evaluate the safety and tolerability of single escalating doses of Peptide YY3-36 and to determine effects on food intake and serum hormones when administered by intravenous infusion to otherwise healthy overweight adult subjects.


Eligibility criteria: Inclusion Criteria:

* BMI 27-35 kg/m2

Exclusion Criteria:

* Women of childbearing potential

Primary outcomes:
measure: Food intake
Secondary outcomes:
measure: Plasma biomarkers, safety, toleration
Other outcomes:
Locations:
city: New Haven
country: United States
facility: Pfizer Investigational Site
state: Connecticut
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References:
Clinical trial NCT06307275: Intermittent Fasting on Body Fat and Quality of Life
Official title: The Effect of Intermittent Fasting on Body Fat and Quality of Life
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Healthy
Lead sponsor: Loma Linda University
Sponsor class: OTHER
First posted: 2024-03-12
Enrollment: 70
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: OTHER

Brief summary: The purpose of this investigator-initiated study to check the feasibility that intermittent fasting has on body fat loss and quality of life.

Detailed description: Start of study: Informed Consent, Body Fat Analysis, Questionnaires on quality of life, sleep, and stress. For the next four weeks, participants will eat their normal food intake with no restrictions on when to eat. Participants will keep their normal weekly exercise routine.

Midway of study: Body Fat Analysis, Questionnaires on quality of life, sleep, and stress. For the next four weeks, participants will do the intermittent fasting program. This program has participants fasting 16 hours from their last meal of the previous evening's meal to the first meal of their next day. Then for 8 hours, participants are able to eat. During the fasting, participants are allowed to consume water and black coffee/tea. Participants will also keep their normal weekly exercise routine.

End of study: Body Fat Analysis, Questionnaires on quality of life, sleep, and stress.

Eligibility criteria: Inclusion Criteria:

• In good health

Exclusion Criteria:

• Diabetes or Metabolic Syndrome

Primary outcomes:
measure: Body fat percentage
timeFrame: change between baseline and eight weeks
measure: Visceral fat
timeFrame: change between baseline and eight weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Loma Linda
country: United States
facility: Loma Linda University
state: California
Study officials:
affiliation: Loma Linda University
name: Gurinder Bains, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05503875: Immunoclassification of Psoriasis: a Strategy for Precision Medicine
Official title: Immunoclassification of Psoriasis: a Strategy for Precision Medicine
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Immunoclassification
Psoriasis
Lead sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Sponsor class: OTHER
First posted: 2022-08-17
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Through the combination of clinical manifestations and omics, the investigators aim to explore the skin cell atlas in different stages of psoriasis lesions, establish a clinical classification standard for psoriasis, and guide the precise treatment of psoriasis.

Detailed description: Psoriasis is a heterogeneous condition that can affect skin and other structures. Over the past decade, considerable advances have been made both in our understanding of the pathogenesis of psoriasis and in the revolutionized immunotherapy of its diverse manifestations. Psoriasis heterogeneity and its cutaneous microenvironment is the leading cause of resistance in patients.

Novel approaches, including single-cell RNA sequencing technology and CyTOF, are proposed as methodological solutions. By their combination with immunotherapy, we can specifically evaluate the mechanism of psoriasis in the face of immunotherapy agents at the single-cell resolution by detecting the transcriptional activity of cytokines, immune checkpoints, screening neoantigens with high transcription levels, identifying rare cells, and assisting the dissection of the critical immune-metabolic pathways in this complex disease. We aim to improve short-term and long-term precision treatment strategies for patients with psoriasis.

Eligibility criteria: Inclusion Criteria:

1.18 to 75 years of age 2.Moderate to severe chronic psoriasis, BSA≥3% 3.Duration of psoriasis≥6 months 4.Patients must be candidate for systemic therapy 5.Informed consent must be obtained 6.For female, ß-hCG test is negative and contraception is accepted

Exclusion Criteria:

1. Having severe infections, including hepatitis, HIV and tuberculosis
2. Having significant allergies to biological agents
3. Having a history of malignancy
4. Refusal of contraception
5. Having serious or unstable/uncontrolled illnesses

Primary outcomes:
measure: Differences in the number of immune cells (dendritic cells, macrophages) in the lesional skin, non-lesional skin of psoriasis patients and healthy skin.
timeFrame: 16 months
measure: Molecular analysis of psoriasis lesional skin by single-cell RNA sequencing.
timeFrame: 16 months
Secondary outcomes:
Other outcomes:
Locations:
city: Hangzhou
country: China
facility: 2nd Affiliated Hospital, School of Medicine, Zhejiang University
state: Zhejiang
Study officials:
References:
Clinical trial NCT05290675: Quantra QPlus Sample Type Comparison
Official title: Impact of Sample Type and Assay Time on the Performance of the Quantra QPlus System
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Coagulation Defect; Bleeding
Keywords: Cardiac surgery
Quantra
Viscoelastic testing
Coagulation
Lead sponsor: HemoSonics LLC
Sponsor class: INDUSTRY
First posted: 2022-03-22
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult males and females undergoing cardiac surgery

Brief summary: This is a single center prospective observational study to compare QPlus parameter measurements in arterial and venous blood samples collected in parallel from patients undergoing cardiac surgery.

Detailed description: In this single center prospective observational study, 40 cardiac surgery subjects will enrolled, each with parallel artrial and venous samples collected at 3 time points to yield 120 matched samples for analysis on the Quantra System with the QPlus Cartridge.

Eligibility criteria: Inclusion Criteria:

* Subject is scheduled for cardiac surgery, utilizing cardiopulmonary bypass, or including placement of a ventricular assist device
* Subject is ≥18 years
* Subject or subject's legally authorized representative is willing to participate and he/she has signed a consent formr.

Exclusion Criteria:

* Subject is younger than 18 years
* Subject is pregnant
* Subject is incarcerated at the time of the study
* Subject is affected by a condition that, in the opinion of the surgical team, may pose additional risks
* Subject, or subject's legally aurthorized representative is able to provide written informed consent

Primary outcomes:
measure: Comparison of QPlus Clot time (CT) in arterial and venous samples
timeFrame: During cardiac surgery
measure: Comparison of QPlus Clot time with Heparinase (CTH) in arterial and venous samples
timeFrame: During cardiac surgery
measure: Comparison of Clot stiffness (CS) determined with Quantra QPlus Cartridge in arterial and venous samples
timeFrame: During cardiac surgery
measure: Comparison of QPlus Platelet Contribution to Clot stiffness (PCS) in arterial and venous samples
timeFrame: During cardiac surgery
measure: Comparison of QPlus Fibrinogen Contribution to Clot stiffness (FCS) in arterial and venous samples
timeFrame: During cardiac surgery
Secondary outcomes:
Other outcomes:
Locations:
city: Columbus
country: United States
facility: Ohio State University Wexner Medical Center
state: Ohio
Study officials:
References:
Clinical trial NCT00926575: Study of orBec® With Prednisone Therapy in the Treatment of Patients With Graft Versus Host Disease (GVHD)
Official title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Safety and Efficacy of orBec® (Oral Beclomethasone 17,21-Dipropionate)in Conjunction With Ten Days of High-Dose Prednisone Therapy in the Treatment of Patients With Gastrointestinal GVHD
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE3
Conditions: Acute Gastrointestinal Graft vs Host Disease
Keywords: BDP
orBec
GVHD
beclomethasone dipropionate
bone marrow transplant
hematopoietic cell transplant
HCT
stem cell transplant
marrow transplant
SCT
beclomethasone 17,21-dipropionate
Lead sponsor: Soligenix
Sponsor class: INDUSTRY
First posted: 2009-06-23
Enrollment: 140
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Use of an oral topically-active glucocorticoid with limited side effects will control the gastrointestinal inflammatory process of GVHD and minimize glucocorticoid exposure.


Eligibility criteria: Inclusion Criteria:

* Receipt of allogeneic hematopoietic cell transplant
* Diagnosis of GI graft vs. host disease (GVHD)
* No GI infection
* Must be able to swallow tablets
* Must be able to read and understand informed consent
* Adequate birth control methods for the duration of the study

Exclusion Criteria:

* Significant Skin GVHD
* Liver GVHD
* Persistent vomiting
* HIV positive
* Pregnancy/lactation

Primary outcomes:
measure: The Proportion of Subjects With GVHD Treatment Failure
timeFrame: Day 80
Secondary outcomes:
measure: Cumulative Exposure to Prednisone
timeFrame: Day 80
measure: Survival Status
timeFrame: Day 200
Other outcomes:
Locations:
city: Buffalo
country: United States
state: New York
city: Durham
country: United States
state: North Carolina
city: Seattle
country: United States
state: Washington
Study officials:
affiliation: Duke University
name: Keith Sullivan, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Fred Hutchinson Cancer Center
name: David Hockenbery, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: McDonald GB, Bouvier M, Hockenbery DM, Stern JM, Gooley T, Farrand A, Murakami C, Levine DS. Oral beclomethasone dipropionate for treatment of intestinal graft-versus-host disease: a randomized, controlled trial. Gastroenterology. 1998 Jul;115(1):28-35. doi: 10.1016/s0016-5085(98)70361-0.
citation: Hockenbery DM, Cruickshank S, Rodell TC, Gooley T, Schuening F, Rowley S, David D, Brunvand M, Berryman B, Abhyankar S, Bouvier M, McDonald GB. A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease. Blood. 2007 May 15;109(10):4557-63. doi: 10.1182/blood-2006-05-021139. Epub 2007 Jan 23.